

#3 2/3/01

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

LIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Dated: February 8, 2001
Nat'l Entry Fr m: PCT/NO99/00143

ATTY DOCKET NO.
1702.401500

APPLICATION NO.
09/674,973

APPLICANT
GUSTAV GAUDERNACK, ET AL.


FILING DATE
Nov mber 8, 2000

GROUP
Unassigned

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT
mm	✓	WO 99/10382	3/1999	WIPO			Yes
	✓	WO 97/12992	4/1997	WIPO			Y s
	✓	WO 96/18409	6/1996	WIPO			Yes
	✓	WO 95/32731	12/1995	WIPO			Yes
mm	✓	WO 92/14756	9/1992	WIPO			Yes

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)	
mm	✓ Rampino et al. (1997), Science 275:967-969, "Somatic Frameshift Mutations in the BAX Gene in Colon Cancers of the Microsatellite Mutator Pheotype".
	✓ Yamamoto et al. (1998, March), Cancer Research 58:997-1003, "Somatic Frameshift Mutations in DNA Mismatch Repair and Proapoptosis Genes in Hereditary Nonpolyposis Colorectal Cancer".
	✓ Markowitz et al. (1995), Science 268:1336-1338, "Inactivation of the Type II TGF-β Receptor in Colon Cancer Cells with Microsatellite Instability".
	✓ Gaudernack (1996), Immunotechnology 2:3-9, "T cell responses against mutant ras: a basis for novel cancer vaccines".
	✓ Gjertsen et al. (1996), Int. Journal of Cancer 65:450-453, "Ex Vivo ras Peptide Vaccination in Patients with Advanced Pancreatic Cancer: Results of a Phase I/II Study".
mm	✓ Gjertsen et al. (1996), British Journal of Cancer 74:1828-1833, "Characterisation of immun responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination".

EXAMINER 

DATE CONSIDERED **07/03**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Dated: February 8, 2001 Nat'l. Entry From: PCT/NO99/00143		ATTY DOCKET NO. 1702.401500		APPLICATION NO. 09/674,973	
APPLICANT GUSTAV GAUDERNACK, ET AL.		FILING DATE November 8, 2000		GROUP Unassigned	

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	

FOREIGN PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT	
<i>mm</i>	WO 99/58564	11/1999	WIPO			Y s	

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)		
<i>mm</i>	<input checked="" type="checkbox"/>	Gjertsen et al. (1997), Int. J. Cancer 72:784-790, "Cytotoxic CD4 ⁺ and CD8 ⁺ T-Lymphocytes, Generated by Mutant p21-ras (12Val) Peptide Vaccination of a Patient, Recognize ... Tumour Cells Carrying This Mutation".
	<input checked="" type="checkbox"/>	Gjertsen et al. (1998) Vox Sanguinis 74(suppl. 2): 489-495, "Mutated Ras Peptides as Vaccines in Immunotherapy of Cancer".
	<input checked="" type="checkbox"/>	Barinaga, (1992) Science, vol. 257, pp. 880-881, "Getting Some 'Backbone': How MHC Binds Peptides".
	<input checked="" type="checkbox"/>	Deres et al., (1989) Nature, vol. 342, pp. 561-564, "In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine".
<i>mm</i>	<input checked="" type="checkbox"/>	Tighe et al., (1998) Immun. Today, vol. 19(2), pp. 89-97, "Gene vaccination: plasmid DNA is more than just a blueprint".

EXAMINER 	DATE CONSIDERED 07/03
--------------	---------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 2 of 2